You are here

New Study, RV306, Begins Screening in Thailand

October 2, 2013
Researchers are using the RV144 vaccine regimen to compare additional vaccine boosts and gather more immunogenicity data in 360 new volunteers.

This study is the second RV144 Follow-up Immunogenicity Study

MHRP initiated several follow-on clinical studies to conduct intensive immunogenicity research on the RV144 vaccine regimen that are funded by NIAID and the U.S. Army. The data from these studies are informing future clinical research by providing insights into the immune mechanisms generated by the RV144 regimen and the effects of an additional boost.

The next follow-on study, RV306 began screening participants in September. In this new study, researchers are using the RV144 vaccine regimen to compare additional vaccine boosts and gather more immunogenicity data in 360 new volunteers. Dr. Punnee Pitisuttithum with Mahidol University is the study Principal Investigator. It will be conducted at three sites: the Vaccine Trial Centre at Mahidol University and the Royal Thai Army Armed Forces Research Institute of Medical Sciences (AFRIMS), both in Bangkok, and the Royal Institute for Health Sciences in Chiang Mai.

The study began on 24 September commemorating Mahidol Day, which marks the passing of Prince Father Mahidol Adulyadej, the "Father of Thai Modern Medicine." It was also on this day, four years ago, that MHRP, NIAID and other partners announced the landmark RV144 trial results.

Another immunogenicity study, RV305, began in April 2012 in Thailand to evaluate re-boosting in volunteers who participated in the RV144 study. Initial data should be available later this year on RV305.